Webdisclosure.com

Search

MEDIOS AG Medios AG: Strong growth in 2019 - Annual forecast slightly exceeded

Directive transparence : information réglementée

06/02/2020 10:00

DGAP-News: Medios AG / Key word(s): Preliminary Results
Medios AG: Strong growth in 2019 - Annual forecast slightly exceeded

06.02.2020 / 10:00
The issuer is solely responsible for the content of this announcement.


Press Release

Medios AG: Strong growth in 2019 - Annual forecast slightly exceeded

Berlin, 6 February 2020 - Medios AG ('Medios'), one of the leading Specialty Pharma companies in Germany, has achieved strong growth in the 2019 financial year and slightly exceeded its annual forecast, which was significantly raised in September. According to preliminary calculations (IFRS), group sales in the period from January to December 2019 increased by 57.6 per cent year-on-year to EUR 516.8 million (previous year EUR 328 million). Group earnings before interest, taxes, depreciation and amortization (EBITDA), adjusted for extraordinary expenses*, rose by 51.5 per cent to EUR 17.8 million (previous year EUR 11.7 million). Group earnings before taxes (EBT), adjusted for extraordinary expenses*, climbed by 47.9 per cent to EUR 16.2 million (previous year EUR 11.0 million). According to its latest forecast, Medios had expected group sales of EUR 500 to 510 million, adjusted EBITDA* of EUR 17 to 18 million and adjusted EBT* of EUR 15 to 16 million.

Manfred Schneider, CEO of Medios AG: 'The 2019 financial year was our most successful in the history of Medios AG. We are convinced that the highly specialized independent local pharmacy has its justification and will further expand this position in the future with our help. This is one reason why we are increasingly winning specialized pharmacies as customers and are permanently expanding our partner network. Another reason is the expansion of our product range to include additional indication areas and increased investment in drug safety.'

Matthias Gärtner, CFO of Medios AG: 'In 2019, we have exceeded the sales mark of half a billion euros for the first time. In the current financial year, we want to continue to grow dynamically and benefit from the consolidation of the pharmaceutical market. Our goal is to become the market leader for Specialty Pharma solutions in Germany.'

The comprehensive consolidated financial statements of Medios AG will be published with the 2019 annual report in April 2020.

-------------------

* EBITDA and EBT are each adjusted proportionately for extraordinary expenses for stock options in the amount of EUR 1.37 million (non-cash) for the 2019 financial year. EBT are also adjusted proportionately for extraordinary expenses for amortization of EUR 0.61 million (non-cash) on the customer base as a result of the acquisition of parts of MediosApotheke Anike Oleski e. Kfr. in the 2019 financial year.

About Medios AG
Medios AG is one of the leading Specialty Pharma companies in Germany. As a specialist for the provision of Specialty Pharma drugs to patients, GMP-certified provider of patient-specific therapies and innovative analytical methods, Medios covers substantial elements of the supply chain in this field and follows the highest international quality standards. Usually, Specialty Pharma drugs are high-priced medicines for rare and/or chronic diseases. Patient-specific therapies are, for example, infusions that are compiled and produced on the basis of individual diseases and parameters like body weight and surface. In the field of drug safety safety, NIR spectroscopic analysis methods (NIR: Near infrared) are used to distinguish marketable finished drugs from drug counterfeits. It is Medios' aim to provide integrated solutions along the value chain to partners and clients, thereby ensuring an optimal pharmaceutical care for patients.

Medios AG is Germany's first publicly listed Specialty Pharma company. The share (WKN: A1MMCC, ISIN: DE000A1MMCC8) is listed in the Regulated Market of the Frankfurt Stock Exchange (General Standard).

Contact
Kirchhoff Consult AG
Nikolaus Hammerschmidt
Borselstraße 20
22765 Hamburg
Germany
Tel.: +49 40 60918618
Fax: +49 40 60918660
E-mail: nikolaus.hammerschmidt@kirchhoff.de
www.kirchhoff.de

Disclaimer
This notification contains forward-looking statements that are subject to certain risks and uncertainties. Future results may significantly deviate from currently expected results, specifically due to various risk factors and uncertainties such as changes in business, economic, and competitive circumstances, exchange rate fluctuations, uncertainties about legal disputes or investigations, and the availability of financial resources. Medios AG assumes no responsibility whatsoever for updating the forward-looking statements contained in this notification.



06.02.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


Language: English
Company: Medios AG
Friedrichstraße 113a
10117 Berlin
Germany
Phone: +49 30 232 566 - 800
Fax: +49 30 232 566 - 801
E-mail: ir@medios.ag
Internet: www.medios.ag
ISIN: DE000A1MMCC8
WKN: A1MMCC
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Dusseldorf
EQS News ID: 969443

 
End of News DGAP News Service

969443  06.02.2020 

fncls.ssp?fn=show_t_gif&application_id=969443&application_name=news&site_id=symex